OBJECTIVES: To understand real world persistence in patients receiving golimumab, adalimumab and etanercept for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) using administrative claims data. METHODS: This study used the MarketScan® Research Database from Thomson Reuters. Patients were diagnosed with RA, PsA, or AS and aged ≥18 years at index date, with continuous enrollment for 6 months prior to and 364 days following the initial medication fill.  Patients had ≥ 2 fills and a 28-31 day supply of study drug (golimumab, adalimumab, or etanercept) for all fills during the 365 day study period.  Patients were matched using propensity score matching for demographic characteristics, and 1:1 matching for prior biologic experience.  Duration of therapy was calculated as date of last dose within the study window minus date of first dose plus the days supply for the last dose.  Treatment persistence was defined as the percentage of time a patient was on therapy during the 365-day study period.  RESULTS: Prior to matching, there were significant differences between the golimumab, adalimumab, and etanercept cohorts in age, gender, geographic region, previous biologic use, last biologic previous to index biologic, primary diagnosis, and psoriasis comorbidity.  In the matched cohorts, no significant differences were found in duration of therapy between the golimumab (259.73 days; 95% CI: 247.20-272.26) and adalimumab (268.75 days; 95% CI: 256.03-281.47) patients or persistence (71.16% [95% CI: 67.73%-74.59%] vs. 73.63% [95% CI: 70.16%-77.10%]). Likewise, there were no significant differences in duration of therapy (267.82 [95% CI: 253.81-281.83] vs. 276.26 days [95% CI: 261.68-290.84]) or persistence (73.38% [95% CI: 69.54-77.22] vs. 75.69% [95% CI: 72.59-78.79]) between the golimumab and etanercept cohorts. CONCLUSIONS: The mean treatment persistence among golimumab patients is over 70%, and when matched to patients taking adalimumab or etanercept, both duration of therapy and persistence are numerically equivalent.